Inside the cardiac screening protocols used at the most rigorous clinics
A review of pre-treatment screening at clinics affiliated with academic research programs reveals consistent practices — and significant variation in how exclusion criteria are applied.
Across the small number of clinics operating in collaboration with academic researchers, cardiac screening before ibogaine administration has converged on a recognizable baseline: a 12-lead electrocardiogram, comprehensive metabolic panel including serum potassium and magnesium, and a history-and-physical focused on cardiac risk factors.
What varies, sometimes substantially, is the threshold at which a candidate is excluded. Some programs treat any QTc above 450 milliseconds as disqualifying; others permit treatment up to 470 ms with continuous telemetry. The literature has not yet produced an evidence-based cutoff.
Reported adverse events — including a small number of fatalities in unregulated settings — have consistently involved either inadequate pre-screening or the presence of polysubstance use that altered the cardiac risk profile in ways that single-time-point screening could not detect.